SCHEMBL946951

SCHEMBL946951

CC(C)(C)[Si](C)(C)OCc1cccc(CCCN2CCOCC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 1/20 0.47
▸ SIGMAR1 Q99720 6/20 0.46
▸ POLB P06746 2/20 0.45
▸ HTT P42858 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ TSHR P16473 2/20 0.41
▸ KCNH2 Q12809 2/20 0.41
▸ CTSK P43235 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ RAD52 P43351 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24915271 0.85 CXCR4 (0.68) CXCR4HTTKMT2AKCNH2ALDH1A1
SCHEMBL947570 0.78 FKBP1A (0.48) POLBHTTALDH1A1KDM4ENPSR1
SCHEMBL947589 0.78 CXCR4 (0.55) CXCR4SIGMAR1POLBHTTKMT2A
SCHEMBL5501972 0.78 CXCR4 (0.55) CXCR4SIGMAR1POLBHTTKMT2A
SCHEMBL950191 0.78 CXCR4 (0.55) CXCR4SIGMAR1POLBHTTKMT2A
SCHEMBL6479913 0.77 PDE10A (0.49) CXCR4GAA
SCHEMBL24915182 0.74 CXCR4 (0.48) CXCR4KMT2AALDH1A1KDM4ENPC1
SCHEMBL4714046 0.73 KCNH2 (0.36) KCNH2NPSR1
SCHEMBL4712759 0.73 HRH1 (0.37) KCNH2NPSR1
SCHEMBL946950 0.73 SIGMAR1 (0.41) CXCR4SIGMAR1POLBHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989446-B2 4-amino 5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-02 — — US disclosed
US-20110009620-A1 4-Amino-5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. 2011-01-13 — — US disclosed
US-7834002-B2 4-amino-5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 — — US disclosed
US-20080182854-A1 4-Amino-5-Cyanopyrimidine Derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-07-31 — — US disclosed
EP-1740574-B1 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES OTSUKA PHARMA CO LTD (JP) 2007-06-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009620-A1 4-Amino-5-cyanopyrimidine derivatives ADORA2A, ADORA1, ADORA3 CXCR4 871/4885SIGMAR1 1884/4885POLB 3905/4885
US-20080182854-A1 4-Amino-5-Cyanopyrimidine Derivatives ADORA2A, ADORA1, ADORA3 CXCR4 871/4885SIGMAR1 1884/4885POLB 3905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback